WeVote

Bill

Bill

HB 263

AN ACT relating to undesignated glucagon.

2026 Regular Session Introduced by Matt Lehman and 1 co-sponsor

HB 263 likely permits broader public access to undesignated glucagon emergency medication for hypoglycemia treatment without individual prescriptions, similar to naloxone policies.

to Health Services (H)
0
WeVote Research Nonpartisan
Bill Summary · HB 263

Legislative bill overview

HB 263 addresses the regulation and distribution of undesignated glucagon—a medication used to treat severe hypoglycemia (dangerously low blood sugar). The bill likely expands access to glucagon by allowing it to be dispensed or administered without being prescribed for a specific individual, similar to how many states now permit public access to naloxone (Narcan) for opioid overdoses.

Why is this important

Severe hypoglycemia is a medical emergency that can cause seizures, loss of consciousness, or death. Making glucagon more readily available in public spaces, workplaces, and schools—without requiring a prescription written for a specific person—could save lives, particularly for people with diabetes who may experience emergencies away from medical supervision. This aligns with public health trends toward broader emergency medication access.

Potential points of contention

  • Liability concerns: Questions about who bears legal responsibility if undesignated glucagon is administered incorrectly or to someone with a contraindication
  • Training and oversight: Whether dispensing undesignated glucagon requires training, or if anyone can administer it without medical guidance
  • Cost and insurance coverage: Whether pharmacies, employers, or health plans must bear costs, and whether Medicaid/Medicare reimbursement applies
  • Implementation details: Specifics on storage, expiration, restocking, and whether this applies to all settings or specific locations

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.